Alpine Immune Sciences Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Alpine Immune Sciences han disminuido a una tasa media anual de -6.1%, mientras que en la industria Biotechs los beneficios crecieron en un 19.3% anualmente. Los ingresos han ido creciendo a una tasa media de 51.3% al año.

Información clave

-6.1%

Tasa de crecimiento de los beneficios

17.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	51.3%
Rentabilidad financiera	-11.1%
Margen neto	-65.2%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Apr 11

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Mar 21

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Mar 20

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Mar 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Feb 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Dec 19

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Sep 23

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Aug 09

Alpine: Rest Before Rallying Again

Apr 25

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Apr 12

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Sep 18

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Aug 18

Desglose de ingresos y gastos

Cómo gana y gasta dinero Alpine Immune Sciences. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:ALPN Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Mar 24	57	-37	24
31 Dec 23	59	-32	22
30 Sep 23	31	-57	20
30 Jun 23	29	-59	19
31 Mar 23	26	-64	19
31 Dec 22	30	-58	18
30 Sep 22	32	-54	18
30 Jun 22	32	-54	17
31 Mar 22	34	-47	16
31 Dec 21	23	-50	15
30 Sep 21	25	-42	13
30 Jun 21	18	-34	12
31 Mar 21	11	-33	12
31 Dec 20	9	-28	11
30 Sep 20	5	-28	10
30 Jun 20	3	-33	10
31 Mar 20	3	-35	9
31 Dec 19	2	-42	9
30 Sep 19	1	-47	10
30 Jun 19	1	-48	9
31 Mar 19	0	-44	9
31 Dec 18	1	-36	8
30 Sep 18	1	-30	7
30 Jun 18	1	-15	7
31 Mar 18	1	-11	6
31 Dec 17	2	-8	5
30 Sep 17	2	-5	4
30 Jun 17	3	-7	2
31 Mar 17	3	-3	2
31 Dec 16	3	-1	1
31 Dec 15	0	0	0

Ingresos de calidad: ALPN actualmente no es rentable.

Margen de beneficios creciente: ALPN actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: ALPN no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 6.1% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de ALPN en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: ALPN no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (16.6%).

Rentabilidad financiera

Alta ROE: ALPN tiene una rentabilidad financiera negativa (-11.07%), ya que actualmente no es rentable.

Alpine Immune Sciences Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Alpine Immune Sciences, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Alpine Immune Sciences Files Form 15

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index

Consensus estimates of losses per share improve by 20%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

New minor risk - Share price stability

Alpine Immune Sciences, Inc Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 10% to US$37.00

Alpine Immune Sciences, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Price target increased by 9.5% to US$33.57

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Price target increased by 11% to US$31.83

Price target increased by 12% to US$30.67

Executive Chairman & CEO exercised options and sold US$1.8m worth of stock

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Executive Chairman & CEO notifies of intention to sell stock

Consensus revenue estimates increase by 12%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $149.9968 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

Alpine Immune Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Alpine Immune Sciences, Inc. Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis

New minor risk - Share price stability

Alpine Immune Sciences, Inc. Announces Appointment of Wolfgang Dummer as Chief Medical Officer

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Alpine Immune Sciences, Inc. Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)

Consensus estimates of losses per share improve by 12%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Consensus revenue estimates fall by 33%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Alpine Immune Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Consensus forecasts updated

Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)

Price target decreased to US$18.33

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences drops 13% after hours on $100M stock offering

Alpine Immune Sciences, Inc. Provides Clinical Updates for Its Two Wholly Owned Programs, ALPN-303 and davoceticept

Consensus EPS estimates fall by 22%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Alpine Immune Sciences, Inc. Announces Board Changes

Alpine Immune Sciences Appoints Andrew S. Sandler as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Alpine Immune Sciences, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Alpine: Rest Before Rallying Again

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Alpine Immune Sciences Announces Oral Presentation at the 2022 AACR Annual Meeting

Insider recently sold US$237k worth of stock